Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).

被引：0
|
作者：
Lee, Keun-Wook
Klempner, Samuel J.
Yang, Jianning
Desai, Amit
Yamada, Akihiro
Ueno, Yoko
Wojtkowski, Tomasz
Park, Jung Wook
Pavese, Janet
Loupakis, Fotios
Bang, Yung-Jue
Shitara, Kohei
机构：
[1] Seoul Natl Univ, Bundang Hosp, Coll, Seongnam, South Korea
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Astellas Pharma Global Dev, Northbrook, IL USA
[4] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[5] Univ Pisana, Univ Azienda Osped, Pisa, Italy
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16078
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.
    Klempner, Samuel J.
    Lee, Keun-Wook
    Metges, Jean-Philippe
    Catenacci, Daniel V. T.
    Loupakis, Fotios
    Ilson, David H.
    Shah, Manish A.
    Shitara, Kohei
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
    Klempner, Samuel J.
    Lee, Keun-Wook
    Shitara, Kohei
    Metges, Jean-Phillippe
    Lonardi, Sara
    Ilson, David H.
    Fazio, Nicola
    Kim, Tae Yong
    Bai, Li-Yuan
    Moran, Diarmuid
    Yang, Jianning
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Bang, Yung-Jue
    Shah, Manish A.
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3882 - 3891
  • [3] Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas
    Shitara, Kohei
    Yamaguchi, Kensei
    Shoji, Hirokazu
    Matsangou, Maria
    Bhattacharya, Pranob P.
    Park, Jung Wook
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-ILUSTRO Cohort 3.
    Klempner, Samuel J.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel V. T.
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie
    Lordick, Florian
    Shah, Manish A.
    Shitara, Kohei
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Van Cutsem, Eric
    Xu Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] SPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Lordick, F.
    Shitara, K.
    Al-Batran, S. -E
    Bang, Y. -J
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218
  • [6] SPOTLIGHT: Phase III study of zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line Claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Shitara, K.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P. C.
    Ilson, D. H.
    Kim, S.
    Lordick, F.
    Shah, M. A.
    van Cutsem, E.
    Xu, R-H.
    Arozullah, A.
    Park, J. W.
    Ajani, J. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1317 - S1317
  • [7] SPOTLIGHT: Comparison of zolbetuximab or placebo+mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
    Yamaguchi, K.
    Shitara, K.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Lordick, F.
    Shah, M.
    Van Cutsem, E.
    Xu, R-H.
    Arozullah, A.
    Park, J. Wook
    Ajani, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Claudin 18.2 determination in locally advanced gastric and gastroesophageal adenocarcinoma treated with neoadjuvant chemotherapy.
    Gervaso, Lorenzo
    Cella, Chiara Alessandra
    Lobrano, Renato
    De Pascale, Stefano
    Benini, Lavinia
    Spada, Francesca
    De Roberto, Giuseppe
    Romario, Uberto Fumagalli
    Rocco, Elena Guerini
    Fazio, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 492 - 492
  • [9] SYMPTOM BURDEN AND HEALTHCARE RESOURCE USE IN CLAUDIN 18.2+(CLDN18.2+), HER2-PATIENTS WITH LOCALLY ADVANCED (LA) UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (MG/GEJ) ADENOCARCINOMA
    Sewastjanow-Silva, M.
    Rogers, J. E.
    Waters, R. E.
    Rosa, Vicentini E.
    Totev, T.
    Wu, Eq
    Yang, H.
    Chang, L.
    Oh, M.
    Ajani, J.
    VALUE IN HEALTH, 2024, 27 (06) : S401 - S401
  • [10] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study
    Lordick, F.
    Shitara, K.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Aprile, G.
    Xu, J.
    Chao, J.
    Pazo-Cid, R.
    Kang, Y. K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116
12345